Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE6D | O43924 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | ESRRA | P11474 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5883824 | 0.92 | CYP2D6 (0.42) | PDE6DALDH1A1HPGDCYP2D6MAPK1 | |
| SCHEMBL5883579 | 0.88 | OPRM1 (0.42) | PDE6DALDH1A1HPGDCYP2D6MAPK1 | |
| SCHEMBL5883779 | 0.87 | PDE6D (0.39) | PDE6DALDH1A1HPGDCYP2D6MAPK1 | |
| SCHEMBL5883739 | 0.86 | ALDH1A1 (0.46) | PDE6DALDH1A1HPGDCYP2D6MAPK1 | |
| SCHEMBL5884152 | 0.81 | PDE6D (0.47) | PDE6DALDH1A1HPGDCYP2D6MAPK1 | |
| SCHEMBL5884184 | 0.81 | PDE6D (0.46) | PDE6DALDH1A1HPGDCYP2D6MAPK1 | |
| SCHEMBL5883736 | 0.80 | NPY1R (0.50) | ALDH1A1PIN1BRD4BAZ2ATP53 | |
| SCHEMBL5883946 | 0.74 | PTGER4 (0.52) | — | |
| SCHEMBL5883743 | 0.72 | HDAC1 (0.51) | HSD17B10PIN1TP53MAPTSMN1; SMN2 | |
| SCHEMBL5883817 | 0.71 | NPY1R (0.53) | HPGDCYP2D6CYP2C19PIN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022714-B2 | Aryl substituted benzimidazoles and their use as sodium channel blockers | EURO-CELTIQUE S.A. (LU) | 2006-04-04 | — | — | US | claimed |
| EP-1532119-A2 | ARYL SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | Euro-Celtique S.A. (LU) | 2005-05-25 | — | — | EP | claimed |
| US-20040132777-A1 | Aryl substituted benzimidazoles and their use as sodium channel blockers | PURDUE PHARMA L.P. | 2004-07-08 | — | — | US | claimed |
| WO-2004011439-A2 | ARYL SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2004-02-05 | — | — | WO | claimed |
| US-7022714-B2 | Aryl substituted benzimidazoles and their use as sodium channel blockers | EURO-CELTIQUE S.A. (LU) | 2006-04-04 | — | — | US | disclosed |
| EP-1532119-A2 | ARYL SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | Euro-Celtique S.A. (LU) | 2005-05-25 | — | — | EP | disclosed |
| US-20040132777-A1 | Aryl substituted benzimidazoles and their use as sodium channel blockers | PURDUE PHARMA L.P. | 2004-07-08 | — | — | US | disclosed |
| WO-2004011439-A2 | ARYL SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS SODIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132777-A1 | Aryl substituted benzimidazoles and their use as sodium channel blockers | CACNA1S, CACNA1I, SCN1A | PDE6D 3882/4885ALDH1A1 135/4885HPGD 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.